Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.
Status:
Active, not recruiting
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This is a prospective, monocentric, open label, phase II trial of intravenous (IV)
Pembrolizumab monotherapy in subjects previously untreated for their stage IIIB-IV, PD-L1 low
non small cell lung cancer (NSCLC).
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano